MASPIN's prognostic role in patients with advanced head and neck carcinoma treated with primary chemotherapy (carboplatin plus vinorelbine) and radiotherapy: Preliminary evidence

Acta Oto-Laryngologica

Volumn 129, Issue 7, 2009, Pages 786-792

  Marioni, Gino ^a   Koussis, Haralabos ^b   Gaio, Elena ^c   Giacomelli, Luciano ^a   Bertolin, Andy ^a   D'Alessandro, Emiliano ^a   Scola, Annamaria ^b   Ottaviano, Giancarlo ^a   De Filippis, Cosimo ^a   Jirillo, Antonio ^b   Staffieri, Alberto ^a   Blandamura, Stella ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Cittadella Civil Hospital   (Italy)

Author keywords

Carboplatin; Head and neck carcinoma; MASPIN; Prognosis; Radiotherapy; Vinorelbine

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; MASPIN; NAVELBINE; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PROGNOSIS; SERINE PROTEINASE INHIBITORS; SERPINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VINBLASTINE;

EID: 72049122421     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480802412789     Document Type: Article

References (20)

1. Erjala K, Raitanen M, Kulmala J, Grenman R. Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 2007;133:169-76.
2. Koussis H, Scola A, Bergamo F, Tonello S, Basso U, Karahontzitis P, et al. Neoadjuvant carboplatin and vinorelbine followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell carcinoma: a phase II study in elderly -70 years) or poor performance status patients. Anticancer Res 2008;28(2B):1383-8.
3. Espinosa E, Zamora P, MilláA, Morales S, Molina R, Mira M, et al. A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 2002;24:1054-9.
4. Helbekkmo N, Sundstrøm SH, AasebøU, Brunsvig PF, von Plessen C, Hjelde HH, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007; 97:283-9.
5. Gebbia V, Mantovani G, Farris A, Agostara B, Desogus A, Curreli L, et al. Vinorelbine, cisplatin and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck. Results of a phase II multicenter study. Cancer 1997;79:1394-400.
6. Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ. Biological functions of maspin. J Cell Physiol 2006;209: 617-624
7. Khalkhali-Ellis Z. Maspin: the new frontier. Clin Cancer Res 2006;12:7279-83.
8. Wang SE, Narasanna A, Whitell CW,Wu FY, Friedman DB, Arteaga CL. Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J Biol Chem 2007;282:5661-9.
9. National Cancer Institute. Reporting Guidelines, Common Toxicity Criteria V2.0 (CTC) [available at: http:/ctep. cancer.gov/reporting/CTC-3.html].
10. Marioni G, Staffieri C, Staffieri A, de Filippis C, Blandamura S. MASPIN tumour-suppressing activity in head and neck squamous cell carcinoma. Emerging evidence and therapeutic perspectives. Acta Otolaryngol 2008 Jul 10:1-5(Epub ahead of print).
11. Xia W, Lau YK, Hu MC, Li L, Johnston DA, Sheng S, et al. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 2000;19:2398-403.
12. Yasumatsu R, Nakashima T, Hirakawa N, Kumamoto Y, Kuratomi Y, Tomita K, et al. Maspin expression in stage I and II oral tongue squamous cell carcinoma. Head Neck 2001;23:962-6.
13. Marioni G, Gaio E, Giacomelli L, Bertolin A, D' Alessandro E, Stramare R, et al. Maspin subcellular localization and expression in oral cavity squamous cell carcinoma. Eur Arch Otorhinolaryngol 2008;265(Suppl. 1):S97-S104.
14. Marioni G, Blandamura S, Giacomelli L, Calgaro N, Segato P, Le G, et al. Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 2005;46:576-82.
15. Marioni G, D'Alessandro E, Giacomelli L, de Filippis C, Calgaro N, Sari M, et al. Maspin nuclear localization is related to reduced density of tumour-associated microvessels in laryngeal carcinoma. Anticancer Res 2006;26: 4927-4932
16. Marioni G, Giacomelli L, D'Alessandro E, Marchese-Ragona R, Staffieri C, Ferraro SM, et al. Nuclear localization of maspin: is its impact on the prognosis in laryngeal carcinoma due to a pro-apoptotic effect? Am J Otolaryngol 2008;29:156-62.
17. Surowiak P, Materna V, Drag-Zalesinska M, Wojner A, Kaplenko I, Spaczyński M, et al. Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates. Int J Gynecol Pathol 2006;25:131-9.
18. Gynecologic Oncology Group. Secord AA, Lee PS, Darcy KM, Havrilesky LJ, Grace LA, Marks JR, et al. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study. Gynecol Oncol 2006;101:390-7.
19. Roncuzzi L, Marti G, Baiocchi D, Del Coco R, Cocchi S, Gasperi-Campani A. Effect of vinorelbine on cell growth and apoptosis induction in human osteosarcoma in vitro. Oncol Rep 2006;15:73-7.
20. Lang DS, Droemann D, Schultz H, Branscheid D, Martin C, Ressmeyer AR, et al. A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy. Respir Res 2007;8:43.